rls

Pramipexole (SND 919) is a selective dopamine receptor agonist used in the therapy of Parkinson disease. Pramipexole therapy is associated with a low rate of transient serum enzyme elevations during treatment but has not been implicated in cases of clinically apparent acute liver injury.

Pramipexole dihydrochloride hydrate (Mirapex) is the hydrochloride salt of pramipexole, a benzothiazole derivative. As a nonergot dopamine agonist, pramipexole binds to D2 and D3 dopamine receptors in the striatum and substantia nigra of the brain.

Pegtarazimod (RLS-0071) inhibits the complement system through both the classical and lectin pathways. It suppresses myeloperoxidase (MPO) activity, leading to reduced ROS production, and decreases the formation of neutrophil extracellular traps (NET). Pegtarazimod exhibits anti-inflammatory properties and is applicable in the study of acute graft-versus-host disease.

Cyclo(RLsKDK) (BK-1361) serves as a targeted inhibitor of the metalloproteinase ADAM8, demonstrating efficacy with an IC50 value of 182 nM. This compound shows promise for use in the treatment of inflammatory diseases and cancer, highlighting its potential therapeutic applications.

Cyclo(RLsKDK) TFA (BK-1361 TFA) is a cyclic peptide and selective ADAM8 metalloproteinase inhibitor, used in research on inflammation and cancer.

Ketorolac tromethamine salt (Ketorolac tris salt) non-selective inhibits the enzymes cyclooxygenase 1 (COX-1) and COX-2with anti-inflammatory, analgesic, and antipyretic activities.

ETH-LAD (N-Ethyl-nor-LSD) is an activator of the 5-HT2A receptor with a Ki value of 5.1 nM. It also has affinity for dopamine receptor D1 and dopamine receptor D2, with Ki values of 22.1 nM and 4.4 nM, respectively. In rat models, ETH-LAD exhibits activity as a psychoactive substance.

AL-LAD (6-Allyl-6-nor-LSD) acts as an agonist of the 5-HT2A receptor (5-HT2A receptor) with a Ki ranging from 3.4 to 8.1 nM. It exhibits significant affinity for dopamine receptor D1 (dopamine receptor D1) and dopamine receptor D2 (dopamine receptor D2), with absolute affinities (K0.5) of 189 nM and 12.3 nM, respectively. In mouse models, AL-LAD functions as a psychoactive compound.

MRL-SYKi is a highly selective and potent chemical probe for spleen tyrosine kinase (SYK). In live cell assays, it strongly binds to SYK gain-of-function (GoF) variants [SYK(S550Y), SYK(S550F), and SYK(P342T)], with IC50 values of 2.1 nM, 14 nM, and 4.6 nM in digitonin-permeabilized cell experiments. MRL-SYKi effectively reduces catalytic activity, as shown in PhosphoSens SOX peptide assays, where the IC50 for SYK(S550F) is 63 nM and for SYK(P342T) is 95 nM. Additionally, it decreases phosphorylation levels at Y525/526 of SYK(S550Y) in SW480 cells. MRL-SYKi is useful for inflammation research.

Compound 39 (NH2-c[X-R-L-S-X]-K-G-P-(D-1Nal)) is a potent agonist of the APJ receptor, possessing a K i value of 0.6 nM. It is capable of activating Gαi1, with an EC 50 of 0.8 nM, and of recruiting β-arrestin2, with an EC 50 of 31 nM. Furthermore, this compound demonstrates extended effects on cardiac function [1].

Compound 40, NH2-c[X-R-L-S-X]-K-G-P-(D-2Nal), a macrocyclic analogue of Ape13, acts as a potent APJ agonist with a Ki of 5.7 nM. It demonstrates favorable Gα12-biased signaling and possesses an enhanced in vivo half-life [1].